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Abstract
Objective: To compare regimens consisting of either ritonavir-boosted atazanavir or efavirenz and a nucleoside reverse
transcriptase inhibitor (NRTI) backbone with respect to clinical, immunologic, and virologic outcomes.
Design:Prospective studies of human immunodeﬁciency virus (HIV)-infected individuals in Europe and the United States included in
the HIV-CAUSAL Collaboration.
Methods: HIV-positive, antiretroviral therapy-naive, and acquired immune deﬁciency syndrome (AIDS)-free individuals were
followed from the time they started an atazanavir or efavirenz regimen. We estimated an analog of the “intention-to-treat” effect for
efavirenz versus atazanavir regimens on clinical, immunologic, and virologic outcomes with adjustment via inverse probability
weighting for time-varying covariates.
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Results: A total of 4301 individuals started an atazanavir regimen (83 deaths, 157 AIDS-deﬁning illnesses or deaths) and 18,786
individuals started an efavirenz regimen (389 deaths, 825 AIDS-deﬁning illnesses or deaths). During amedian follow-up of 31months,
the hazard ratios (95% conﬁdence intervals) were 0.98 (0.77, 1.24) for death and 1.09 (0.91, 1.30) for AIDS-deﬁning illness or death
comparing efavirenz with atazanavir regimens. The 5-year survival difference was 0.1% (95% conﬁdence interval:0.7%, 0.8%) and
the AIDS-free survival difference was 0.3% (1.2%, 0.6%). After 12 months, the mean change in CD4 cell count was 20.8 (95%
conﬁdence interval: 13.9, 27.8) cells/mm3 lower and the risk of virologic failure was 20% (14%, 26%) lower in the efavirenz regimens.
Conclusion:Our estimates are consistent with a smaller 12-month increase in CD4 cell count, and a smaller risk of virologic failure
at 12 months for efavirenz compared with atazanavir regimens. No overall differences could be detected with respect to 5-year
survival or AIDS-free survival.
Abbreviations: AIDS = acquired immune deﬁciency syndrome, ANRS = Agence Nationale de Recherches sur le SIDA, INSTI =
integrase strand transfer inhibitor, NNRTI = nonnucleoside reverse transcriptase inhibitor, NRTI = nucleoside reverse transcriptase
inhibitor, PI = protease inhibitor.
Keywords: atazanavir, efavirenz, HIV, mortality, observational studies
1. Introduction
Until recently, most clinical guidelines for human immunodeﬁ-
ciency virus (HIV)-positive individuals recommended 1st-line
regimens consisting of either a ritonavir-boosted protease
inhibitor (PI) or a nonnucleoside reverse transcriptase inhibitor
(NNRTI) in combination with 2 nucleoside reverse transcriptase
inhibitors (NRTIs). One of the most commonly prescribed
boosted PIs was atazanavir and one of the most commonly
prescribed NNRTIs was efavirenz. The European acquired
immune deﬁciency syndrome (AIDS) Clinical Society, the
Department of Health andHuman Services, and the International
AIDS Society USA Panel all currently recommend atazanavir and
efavirenz equally while the British HIV Association recommends
atazanavir over efavirenz.[1–4] However, in the most recent
Department of Health and Human Services guidelines, both
atazanavir and efavirenz were moved from recommended to
alternative in favor of integrase strand transfer inhibitors
(INSTIs) and darunavir. The World Health Organization
recommends efavirenz as part of 1st-line therapy and atazanavir
as part of 2nd-line therapy.[5] In resource-limited settings,
efavirenz and atazanavir remain cornerstones of antiretroviral
therapy.
The comparative effectiveness of regimens based on ritonavir-
boosted atazanavir and efavirenz is, however, incomplete. Two
randomized clinical trials[6,7] and 3 observational studies[8–10]
studied short-term virologic and immunologic outcomes with
inconclusive results. All these studies were relatively small and
few had follow-up times sufﬁcient for the assessment of clinical
outcomes such as death and AIDS-deﬁning illness.
Here we examine clinical, immunologic, and virologic out-
comes among AIDS-free individuals who started a 1st-line
regimen consisting of either efavirenz or ritonavir-boosted
atazanavir with different types of NRTI-backbones in a large




The HIV-CAUSAL Collaboration has been described else-
where.[11] Brieﬂy, the collaboration includes several prospective
cohort studies from 6 European countries and the United States:
UK CHIC (United Kingdom Collaborative HIV Cohort),
ATHENA (AIDS Therapy Evaluation in the Netherlands),
FHDH-ANRS CO4 (French Hospital Database on HIV-Agence
Nationale de Recherches sur le SIDA), Aquitaine (France), SHCS
(Swiss HIV Cohort Study), PISCIS (Proyecto para la Informa-
tización del Seguimiento Clinicoepidemiológico de la Infección
por HIV y SIDA [Spain]), CoRIS (Cohorte de la Red de
Investigación en SIDA [Spain]), VACS-VC (Veterans Aging
Cohort Study-Virtual Cohort [United States]), AMACS (Athens
Multicenter AIDS Cohort Study [Greece]), UK Register of HIV
Seroconverters, ANRS PRIMO and ANRS SEROCO (Agence
Nationale de Recherches sur le SIDA [France]), and GEMES
(Grupo Espanõl Multicéntrico para el Estudio de Seroconver-
tores-Haemophilia [Spain]). All cohorts included in the HIV-
CAUSAL Collaboration were assembled prospectively and are
based on data collected for clinical purposes within national
healthcare systems with universal access to care. Each cohort in
the collaboration collects all CD4 cell counts, HIV-1 RNAs,
treatment initiations, AIDS-deﬁning illnesses, and deaths.
For each individual, follow-up started at the initiation of a 1st-
line antiretroviral regimen containing either efavirenz or
atazanavir (baseline). Our analysis was restricted to HIV-positive
individuals who met the following eligibility criteria at baseline
dates between January 2004 and January 2013: age 18 years or
older, previously antiretroviral therapy-naive, no history of an
AIDS-deﬁning illness,[12] not pregnant (when information was
available), and CD4 cell count and HIV-1 RNA measurements
within 6 months prior to baseline. For the analysis of clinical
outcomes, follow-up ended at the occurrence of the outcome, 12
months after the most recent laboratory measurement (i.e., we
considered an individual to be lost to follow-up if and when he
had no new CD4 or HIV-1 RNA measurements for 12 months),
pregnancy (if known), or the cohort-speciﬁc administrative end of
follow-up (ranging from September 2010 to March 2013),
whichever occurred ﬁrst. For the analysis of immunologic and
virologic outcomes, follow-up ended on average at 12 months
after baseline.
2.2. Outcomes
We considered clinical, immunologic, and virologic outcomes.
The clinical outcomes of interest were death from any cause and
clinical AIDS-deﬁning illness[12] or death. Dates of death were
identiﬁed using a combination of national and local mortality
registries and clinical records as described elsewhere,[11]
and AIDS-deﬁning illnesses were ascertained by the treating
physicians.
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Themain immunologic and virologic outcomes of interest were
the 12-month change in CD4 cell count after baseline and
virologic failure deﬁned as HIV-RNA>50copies/mL at 12
months, respectively. Our deﬁnition of virologic failure was
chosen to allow for comparison with the results from the trials.
Although a single measurement of HIV-RNA>50copies/mL
could be a viral blip as opposed to a failure, our results would
only be affected if the frequency of blips varies by antiretroviral
regimen. If CD4 cell count or HIV-RNA was not measured
exactly 12 months after baseline, we used the closest measure-
ment within 2 months. In secondary analyses, we also studied the
CD4 cell count and virologic failure at 24 months.
2.3. Antiretroviral regimens
We considered 2 types of 1st-line regimens: efavirenz and
atazanavir regimens. The analysis was restricted to individuals
who started an NRTI backbone and either efavirenz or ritonavir-
boosted atazanavir at baseline. Individuals were excluded if they
started an ineligible drug (i.e., an INSTI, a fusion inhibitor, an
NNRTI other than efavirenz, or a PI other than ritonavir/
atazanavir) or both efavirenz and atazanavir at baseline.
In our main analysis, we allowed efavirenz or ritonavir-
boosted atazanavir to be paired with any NRTI backbone. In
subgroup analyses, we included those backbones that appear in
the most recent guidelines[1–4] or that were used in the
randomized trials.[6,7] Speciﬁcally, we focused on the backbones
abacavir/lamivudine and tenofovir/emtricitabine.
2.4. Statistical methods
We ﬁt pooled logistic models to estimate the hazard ratio of each
clinical outcome for efavirenz versus atazanavir regimens. Both
models included a regimen indicator (1: efavirenz, 0: atazanavir),
cohort, month of follow-up (modeled as a restricted cubic spline
with 4 knots at 1, 6, 24, and 60 months), and the following
baseline covariates: sex, age (<35, 35–49, ≥50 years), race
(white, black, other or unknown), geographic origin (Western
countries, sub-Saharan Africa, other, or unknown), mode of HIV
acquisition (heterosexual, homosexual/bisexual, injection drug
use, other or unknown), CD4 cell count (<200, 200–299,
300–399, 400–499, and ≥500cells/mm3), HIV-1 RNA
(<10,000, 10,000–100,000, and>100,000copies/mL), calendar
year (2004–2007, ≥2008), and years since HIV diagnosis (<1,
1–4,≥5 years or unknown). For the immunologic outcome, we ﬁt
a linear regression model with the same covariates to estimate the
12-month change in CD4 cell count for efavirenz versus
atazanavir regimens among those with measurements at 12±2
months. For the virologic outcome, we ﬁt a modiﬁed Poisson
regression model[13] with the same covariates to estimate the risk
ratio of virologic failure at 12 months for efavirenz versus
atazanavir regimens among those with measurements at 12±2
months.
In the analyses of the immunologic and virologic outcomes,
some individuals did not have a measurement during the interval
12±2 months after baseline. To adjust for potential selection
bias, we estimated stabilized inverse probability weights[14] of
having a measurement via pooled logistic models for artiﬁcial
censoring that included the time-ﬁxed covariates and time-
varying CD4 cell count (<200, 200–299, 300–399, 400–499,
and ≥500cells/mm3), HIV-1 RNA (<10,000, 10,000–100,000,
and >100,000copies/mL), and month of last laboratory
measurement (continuous).
Under the assumption that we measured and successfully
adjusted for all confounders, the estimated coefﬁcient for the
regimen indicator in the adjusted models is analogous to the
“intention-to-treat” effect that would have been estimated from
an open-label randomized trial with similar adherence and
follow-up. Because we deﬁned the clinical regimens of interest in
terms of the 1st-line regimen only, it was unnecessary to adjust for
joint determinants of switching and death.
For the 2 clinical outcomes, we also estimated absolute risks by
ﬁtting adjusted models like the one described above that also
included product (“interaction”) terms between the regimen
indicator and month of follow-up with spline terms. The
predicted values from the models were then used to estimate
the 5-year survival and 5-year AIDS-free survival curves from
baseline.
2.5. Subgroup and sensitivity analyses
For all outcomes, we compared efavirenz and atazanavir in
subgroups deﬁned by baseline calendar year, sex, age, mode of
HIV acquisition, baseline CD4 cell count, and baseline HIV-1
RNA.
Because the lower limit of detection was unknown in <5% of
observations with HIV-1 RNA between 50 and 400copies/mL,
we conducted a sensitivity analysis in which we deﬁned virologic
failure as HIV-1 RNA >400copies/mL.
In another sensitivity analysis, we allowed a 6-month grace
period for individuals to complete one of the regimens of interest
as opposed to requiring individuals to start all of the drugs in their
regimen simultaneously. Follow-up on individuals was artiﬁcially
censored if and when they started an ineligible drug before
completing a regimen or at 6 months from baseline if their
regimen was not yet complete. As previously described, to adjust
for potential selection bias due to the artiﬁcial censoring, we
estimated unstabilized inverse probability weights[14] via pooled
logistic models for artiﬁcial censoring that included the time-ﬁxed
covariates and time-varying CD4 cell count (restricted cubic
spline with 5 knots at 10, 200, 350, 500, and 1000 cells/mm3),
HIV-1 RNA (<10,000, 10,000–100,000, and >100,000 copies/
mL), AIDS-deﬁning illness (when the outcome was death alone),
and time since last laboratory measurement (0, 1–2, 3–4, 5–6,
and ≥7 months).
Several other sensitivity analyses were also performed. For all 4
outcomes, we used continuous as opposed to categorical baseline
covariates and investigated the effect of including chronic
hepatitis C infection[15] as a baseline covariate. For the clinical
outcomes, we weighted individuals’ contributions to the models
by the inverse of their probability of remaining uncensored due to
infrequent laboratory measurements. For the immunologic and
virologic outcomes, we also weighted by the inverse probability
of remaining alive at 12±2 months after baseline as a form of
competing risks analysis.
All 95% CIs were estimated via a nonparametric bootstrap
with 500 samples. All analyses were conducted with SAS 9.3 (SAS
Institute, Cary, NC). The institutional review board at Harvard
T.H. Chan School of Public Health approved our research.
3. Results
The dataset included 23,087 individuals of which 4301 followed
an atazanavir regimen and 18,786 followed an efavirenz regimen.
Table 1 shows the characteristics of the study population by
regimen type at baseline. A higher proportion of women, those
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Table 2
Clinical and virologic outcomes by recommended nucleoside reverse transcriptase inhibitor backbone for regimens based on efavirenz
versus atazanavir, HIV-CAUSAL Collaboration 2004 to 2013.
Backbone
No. of individuals/
No. deaths/No. of AIDS or deaths Death AIDS or death Virologic failure
Atazanavir Efavirenz Hazard ratio
∗,† (95% CI) Hazard ratio
∗,† (95% CI) Risk ratio
∗,‡ (95% CI)
All backbones 4301/83/157 18,786/389/825 0.98 (0.77, 1.24) 1.09 (0.91, 1.30) 0.80 (0.74, 0.86)
Abacavir/lamivudine 658/9/23 1629/38/85 2.52 (1.04, 6.10) 1.71 (0.99, 2.94) 0.76 (0.58, 0.98)
Tenofovir/emtricitabine 3286/43/96 14,247/218/479 1.16 (0.82, 1.63) 1.15 (0.91, 1.45) 0.77 (0.70, 0.85)
Abacavir/lamivudine and
tenofovir/emtricitabine
3944/52/119 15,876/256/564 1.23 (0.90, 1.67) 1.17 (0.96, 1.42) 0.77 (0.70, 0.83)
AIDS= acquired immune deﬁciency syndrome, CI= conﬁdence interval, HIV=human immunodeﬁciency virus, No.=number.
∗
Adjusted for the baseline covariates (sex, age, race, geographic origin, mode of transmission, CD4 cell count, HIV-1 RNA, calendar year, and years since HIV diagnosis).
† Hazard ratio of efavirenz versus atazanavir.
‡ Risk ratio of efavirenz versus atazanavir based on 2878 and 13,643 individuals with HIV-1 RNA measurements at 12±2 months in the atazanavir and efavirenz groups, respectively.
Table 1
Characteristics of 23,087 therapy-naive HIV-positive individuals at baseline, HIV-CAUSAL Collaboration 2004 to 2013.
Characteristic No. of individuals, %
Atazanavir Efavirenz Total
(n=4301) (n=18,786) (n=23,087)
Sex Men 3372 (78.4) 16,021 (85.3) 19,393 (84)
Women 929 (21.6) 2765 (14.7) 3694 (16)
Age, years <35 1435 (33.4) 6436 (34.3) 7871 (34.1)
35–50 2035 (47.3) 8883 (47.3) 10,918 (47.3)
>50 831 (19.3) 3467 (18.5) 4298 (18.6)
Geographic origin Western countries 3215 (74.8) 13,589 (72.3) 16,804 (72.8)
Sub-Saharan Africa 601 (14) 2423 (12.9) 3024 (13.1)
Other 348 (8.1) 1755 (9.3) 2103 (9.1)
Unknown 137 (3.2) 1019 (5.4) 1156 (5)
Acquisition group Heterosexual 1444 (33.6) 5118 (27.2) 6562 (28.4)
Homosexual 1892 (44) 9597 (51.1) 11,489 (49.8)
Injection drug use 187 (4.3) 492 (2.6) 679 (2.9)
Other/unknown
∗
778 (18.1) 3579 (19.1) 4357 (18.9)
CD4 cell count, per mm3 <200 1226 (28.5) 5246 (27.9) 6472 (28)
200–299 1245 (28.9) 6124 (32.6) 7369 (31.9)
300–399 1030 (23.9) 4513 (24) 5543 (24)
400–499 427 (9.9) 1587 (8.4) 2014 (8.7)
≥500 373 (8.7) 1316 (7) 1689 (7.3)
HIV-1 RNA, copies/mL <10,000 827 (19.2) 3473 (18.5) 4300 (18.6)
10,000–100,000 1958 (45.5) 8805 (46.9) 10,763 (46.6)
>100,000 1516 (35.2) 6508 (34.6) 8024 (34.8)
Calendar year 2004–2007 1296 (30.1) 6799 (36.2) 8195 (35.5)
≥2008 3005 (69.9) 11,987 (63.8) 14,892 (64.5)
Cohort UK CHIC 704 (16.4) 5174 (27.5) 5878 (25.5)
ATHENA 380 (8.8) 2749 (14.6) 3129 (13.6)
FHDH-ANRS CO4 1491 (34.7) 2778 (14.8) 4269 (18.5)
Aquitaine 322 (7.5) 916 (4.9) 1238 (5.4)
SHCS 421 (9.8) 2094 (11.1) 2515 (10.9)
PISCIS/AMACS 182 (4.2) 1609 (8.6) 1791 (7.8)
CoRIS 152 (3.5) 658 (3.5) 810 (3.5)
Seroconverters† 553 (12.9) 2646 (14.1) 3199 (13.9)
VACS-VC 96 (2.2) 162 (0.9) 258 (1.1)
Hepatitis C infection Deﬁnite/Probable 116 (2.7) 557 (3) 673 (2.9)
Possible 139 (3.2) 467 (2.5) 606 (2.6)
None 4046 (94.1) 17,762 (94.5) 21,808 (94.5)
AMACS=Athens Multicenter AIDS Cohort Study, ANRS=Agence Nationale de Recherches sur le SIDA, ATHENA=AIDS Therapy Evaluation in the Netherlands, CoRIS=Cohorte de la Red de Investigación en
SIDA, FHDH= French Hospital Database on HIV, GEMES=Grupo Español Multicéntrico para el Estudio de Seroconvertores-Hemoﬁlia, HIV=human immunodeﬁciency virus, PISCIS=Proyecto para la
Informatización del Seguimiento Clinicoepidemiológico de la Infección por HIV y SIDA, SHCS=Swiss HIV Cohort Study, UK CHIC=United Kingdom Collaborative HIV Cohort, VACS-VC=Veterans Aging Cohort
Study-Virtual Cohort.
∗
Other/Unknown acquisition group included all VACS-VC participants.
† Includes the UK Register of HIV Seroconverters, ANRS PRIMO, ANRS SEROCO, and GEMES cohorts.
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who acquired HIV through heterosexual transmission, and those
starting treatment in 2008 or later, initiated atazanavir than
efavirenz.
As shown in Table 2, 83 individuals died and 157 developed
an AIDS-deﬁning illness or died among those initiating an
atazanavir regimen, and 389 individuals died and 825 developed
an AIDS-deﬁning illness or died among those initiating an
efavirenz regimen. In the mortality analysis, the median
(interquartile range) follow-up time was 27 (14, 45) months
for the atazanavir regimens and 32 (17, 52) months for the
efavirenz regimens. A total of 956 (22%) individuals following an
atazanavir regimen and 4617 (25%) following an efavirenz
regimen were lost to follow-up. The numbers were similar in the
AIDS or death analysis. Compared with atazanavir, the hazard
ratio (95% CI) for efavirenz was 0.98 (0.77, 1.24) for death and
1.09 (0.91, 1.30) for AIDS or death.
Figure 1 plots the estimated 5-year survival and 5-year AIDS-
free survival with all backbones. The 5-year survival was 96.9%
(96.3%, 97.6%) for the atazanavir regimens and 97.0% (96.7%,
97.4%) for the efavirenz regimens. The survival difference was
0.1% (0.7%, 0.8%) at 5 years. The 5-year AIDS-free survival
proportion was 94.6% (93.7%, 95.5%) for the atazanavir
regimens and 94.3% (93.9%, 94.7%) for the efavirenz regimens.
The AIDS-free survival difference was 0.3% (1.2%, 0.6%) at
5 years.
Table 2 also provides the risk ratios of virologic failure at 12±
2 months comparing efavirenz with atazanavir. Among those
initiating atazanavir and efavirenz regimens, 683/2878 (24%)
and 2644/13,643 (19%) had HIV-1 RNA >50copies/mL at
12 months, respectively. Compared with atazanavir, the risk
ratio of virologic failure at 12 months for efavirenz was 0.80
(0.74, 0.86). Results were similar in subgroups deﬁned by
backbone. Among those initiating atazanavir and efavirenz
regimens, 19% and 15% had HIV-1 RNA >50copies/mL at 24
months, respectively. Compared with atazanavir, the risk ratio of
virologic failure at 24months for efavirenz was 0.81 (0.74, 0.89).
Figure 2 shows the 12-month adjusted mean change in CD4
cell count by backbone. Comparedwith atazanavir, the estimated
mean change in CD4 cell count (95%CI) for efavirenz was20.8
(27.8, 13.9) for all backbones. The mean CD4 cell count
would have increased from 280 to 495cells/mm3 over 12 months
had all individuals taken an atazanavir regimen, and from 280 to
474cells/mm3 had all individuals taken an efavirenz regimen.
Results were similar in subgroups deﬁned by backbone.
Compared with atazanavir, the estimated mean change in
CD4 cell count over 24 months (95% CI) for efavirenz was
15.6 (25.3, 5.9).
Most individuals initiated a backbone of either abacavir/
lamivudine (10%) or tenofovir/emtricitabine (76%). Abacavir/
lamivudine was used more frequently with atazanavir, while
tenofovir/emtricitabine were used equally with atazanavir and
efavirenz. In the subgroup of individuals using 1 of these 2
backbones, the hazard ratio for efavirenz was 1.23 (0.90, 1.67)
for death and 1.17 (0.96, 1.42) for AIDS or death (Table 2).
None of the sensitivity analyses yielded appreciably different
results (data not shown). In subgroup analyses, estimates for all 4
outcomes were similar when we restricted to baseline years 2008
and beyond, men, those aged less than 50 years, noninjection
drug users, those with baseline CD4 cell counts below 350cells/
mm3, those with baseline viral loads above 100,000copies/mL,
and those from Western countries. When we deﬁned virologic
Figure 1. Survival (left) and AIDS-free survival (right) for efavirenz versus atazanavir, HIV-CAUSAL Collaboration 2004 to 2013. The curves are standardized by the
baseline covariates listed under Table 2.























Figure 2. Immunologic outcomes by recommended NRTI backbone for
regimens based on efavirenz versus atazanavir, HIV-CAUSAL Collaboration
2004 to 2013. 3TC= lamivudine, ABC=abacavir, FTC=emtricitabine, HIV=
human immunodeﬁciency virus, NRTI=nucleoside reverse transcriptase
inhibitor, TDF= tenofovir.
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failure as HIV-1 RNA >400copies/mL, the percentage with
virologic failure decreased, but the risk ratio comparing efavirenz
with atazanavir remained similar. Finally, allowing a 6-month
grace period for individuals to complete one of the regimens of
interest had little effect on the estimates.
4. Discussion
The clinical effectiveness of efavirenz versus ritonavir-boosted
atazanavir has not been directly studied in randomized trials,
which have focused on short-term immunologic and virologic
outcomes. Our study compared efavirenz versus atazanavir
regimens with respect to clinical outcomes among antiretroviral-
naive, AIDS-free individuals in Europe and the United States. We
did not detect any differences in mortality or AIDS-deﬁning
illness.
We also found that individuals on efavirenz regimens were
20% less likely to have virologic failure at 12 months as those on
atazanavir regimens and experienced a smaller 12-month
increase in CD4 cell count by 20.8cells/mm3. This absolute
difference in CD4 cell count was small and of questionable
clinical relevance, especially for greater than 450cells/mm3 CD4
cell counts that are expected in our study at 12 months.
Our virologic and immunologic ﬁndings were consistent with
those of the 2 previous trials.[6,7] The Altair Study found that the
mean change in CD4 cell count was 5cells/mm3 higher in the
atazanavir arm than in the efavirenz arm over 48 weeks. The
A5202 study estimated the median change in CD4 cell count and
found a 10cells/mm3 greater increase in the efavirenz armwhen a
backbone of abacavir/lamivudine was used and a 12cells/mm3
smaller increase in the efavirenz arm when a backbone of
tenofovir/emtricitabine was used compared with the atazanavir
arm. Like in our study, these differences were small and of little
clinical relevance. The A5202 study found advantages of
efavirenz over atazanavir with respect to virologic failure at
48 weeks, but little association was found in the Altair study.
Our estimates are based on less restrictive inclusion criteria,
and therefore are potentially more relevant to the general
population of HIV-infected individuals than those of the trials.
Speciﬁcally, both trials restricted to individuals with baseline
HIV-1 RNA≥5000copies/mL and included some individuals
who were not AIDS-free at baseline. The trials also excluded
those with low CD4 cell counts (Altair study: 50cells/mm3,
A5202 study: 100cells/mm3 if prior AIDS, 75cells/mm3 if not
prior AIDS). When we restrict to individuals with baseline HIV-1
RNA≥5000copies/mL, CD4≥50cells/mm3, and to one of the
backbones used in the trials, the 12-month adjusted mean change
in CD4 cell count for efavirenz versus atazanavir was 22.8
(30.5,15.1) and the risk ratio of virologic failure at 12months
for efavirenz versus atazanavir was 0.77 (0.71, 0.85). We
compared these estimates to those from a meta-analysis
we conducted with the published information in the 2 trials.
This virologic result was not as strong as the result of the meta-
analysis: 0.65 (0.49, 0.85). Unfortunately, we were unable to
conduct a meta-analysis using the available information for CD4
cell count change.
In the Altair study, both arms had a backbone of tenofovir/
emtricitabine. In the A5202 study, both arms had a backbone of
either tenofovir/emtricitabine or abacavir/lamivudine. In our
main analysis, any backbone could be used. We also conducted
analyses restricted to the backbones used in the trials. Results in
subgroups deﬁned by backbone were similar to those for all
backbones with the exception of the clinical outcomes when
abacavir/lamivudine was used. However, these results were based
on few events and conﬁdence intervals were wide.
Like all observational estimates, ours rely on the untestable
assumption that we have successfully measured and adjusted for
all confounders. In this analysis, we measured and adjusted for
sex, age, race, geographic origin, mode of HIV acquisition, CD4
cell count, HIV-1 RNA, calendar year, and years since HIV
diagnosis. If further adjustment is necessary to account for
confounding factors responsible for large prognostic differences
between patients initiating efavirenz versus atazanavir, the
assumption would not hold.
One of these confounding factors might be adherence.
Atazanavir was independently associated with suboptimal
adherence in a study of individuals from the SMART study.[16]
Atazanavir also has a higher genetic barrier to resistance than
efavirenz.[7] These facts may suggest that atazanavir was more
often prescribed to individuals whose future adherence was
questionable (e.g., because of markers of poor health such as
cardiovascular disease). However, we measured and adjusted for
several proxies for adherence, including HIV-1 RNA, calendar
year, intravenous drug use, years since HIV diagnosis, and time
since last laboratory measurement.
In addition, during the course of this study, both drugs may
have been used in a way that is no longer considered optimal.
Efavirenz is contraindicated for patients with psychiatric illness
and pregnant women, while ritonavir-boosted atazanavir is not
recommended for use with antacids and other drugs that raise
gastric pH.[2] Although our data did not allow us to investigate
psychiatric illness or the use of nonantiretroviral drugs, we
excluded women known to be pregnant in all analyses. The
magnitude of the reported association makes it unlikely that our
immunologic and virologic estimates can be fully explained by
the use of antacids, anti-psychotics, or other drugs.
In summary, our ﬁndings extend those of randomized trials
from immunologic and virologic outcomes to clinical outcomes.
Our ﬁndings do not support changes to the current clinical
guidelines for HIV-positive individuals, but the new evidence
presented here may be informative to those drafting the next set
of guidelines. Future studies need to consider the effects of
efavirenz and atazanavir on other clinical outcomes including
non-AIDS-deﬁning illnesses, when paired with speciﬁc backbones
and over longer periods. This is particularly true in resource-
limited settings and other areas where efavirenz and atazanavir
are needed as antiretroviral therapy alternatives.
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Monge, Y Rivero, C González. Participating centres: Hospital
General Universitario de Alicante, Alicante: J Portilla, E Merino,
S Reus, V Boix, L Giner, C Gadea, I Portilla, P Arcaina, Hospital
Universitario de Canarias, Santa Cruz de Tenerife (JL Gómez
Sirvent, P Rodríguez, MR Alemán, MM Alonso, AM López, MI
Hernández, F Díaz-Flores), Hospital Carlos III, Madrid (V
Soriano, P Labarga, P Barreiro, P Rivas, F Blanco, ME Vispo, L
Martín, C Solera), Hospital Universitario Central de Asturias,
Oviedo: V Asensi, E Valle, JA Cartón, Hospital Doce de Octubre,
Madrid (R Rubio, F Pulido S Fiorante, J Llenas, V Rodríguez, M
Matarranz), Hospital Donostia, San Sebastián (JA Iribarren, J
Arrizabalaga, MJ Aramburu, X Camino, F Rodríguez-Arrondo,
MA vonWichmann, L Pascual,MAGoenaga,MJ Bustinduy, HA
Galparsoro), Hospital General Universitario de Elche (F
Gutiérrez, M Masiá, C López, S Padilla, A Navarro, F
Montolio,C Robledano, JG Colomé), Hospital Gregorio Mar-
añón, Madrid (J Berenguer, JC López, P Miralles, J Cosín, I
Gutiérrez, M Ramírez, B Padilla, P Gijón, A Carrero, T Aldamiz-
Echevarría, F Tejerina), Hospital Universitari de Tarragona Joan
XXIII (F Vidal, J Peraire, S Veloso, C Viladés,M López-Dupla,M
Olona, M Vargas, A Aguilar, JJ Sirvent, V Alba, O Calavia),
Hospital La Fe, Valencia (JL Aldeguer, M Blanes, J Lacruz, M
Salavert, M Montero, E Calabuig, S Cuéllar), Hospital
Universitario La Paz, Madrid: J González, I Bernardino, JR
Arribas, ML Montes, JM Peña, B Arribas, JM Castro, FJ
Zamora, I Pérez, M Estébanez, S García, M Díaz, Hospital de la
Princesa, Madrid (I de los Santos, J Sanz, A Salas, C Sarriá),
Hospital San Pedro, Logroño (JA Oteo, JR Blanco, V Ibarra, L
Metola, M Sanz, L Pérez-Martínez, J Pinilla), Hospital
Universitario Mutua de Terrassa, Terrassa: D Dalmau, A Jaén,
M Cairó, D Irigoyen, L Ibáñez, Q Jordano, M Xercavins, J
Martinez-Lacasa, P Velli, R Font, Hospital de Navarra,
Pamplona (M Rivero, MI Casado, JA Díaz, J Uriz, J Reparaz,
MJ Arriaza, C Irigoyen), Hospital Ramón y Cajal, Madrid (S
Moreno, JL Casado, F Dronda, AMoreno,MJ Pérez, D López, C
Gutiérrez, B Hernández, M Pumares, P Martí), Hospital Reina
Sofía, Murcia: A Cano, E Bernal, AMuñoz, Hospital San Cecilio,
Granada (F García, J Hernández, A Peña, L Muñoz, J Parra),
Centro Sanitario Sandoval, Madrid: J Del Romero, C Rodríguez,
T Puerta, JC Carrió, C González, M Vera, Hospital Universitario
Santiago de Compostela, Santiago de Compostela: A Antela, A
Prieto, E Losada, Hospital Universitario de Valme, Sevilla: JA
Pineda, E Recio, F Lozano, J Macías, J del Valle, J Gómez-
Mateos, Hospital Virgen de la Victoria, Málaga: J Santos, M
Márquez, I Viciana, R Palacios, Hospital Universitario Virgen del
Rocío, Sevilla (P Viciana, M Leal, LF López-Cortés, M Trastoy).
Veterans Aging Cohort Study: Consortium PD: AC Justice∗.
Scientiﬁc Collaborator (NIAAA): K Bryant, Afﬁliated PIs: S
Braithwaite, K Crothers∗, R Dubrow, DA Fiellin∗, M Freiberg∗,
V LoRe∗, K Kraemer. Participating VAMedical Centers: Atlanta
(V Marconi∗), Baltimore (M Sajadi, R Titanji), Bronx (S Brown,
Y Ponomarenko), Dallas (R Bedimo∗), Houston (M Rodriguez-
Barradas, N Masozera), Los Angeles (M Goetz, D Leaf),
Manhattan-Brooklyn (M Simberkoff, D Blumenthal, H Leaf, J
Leung), Pittsburgh (A Butt, K Kraemer, E Hoffman), and
Washington DC (C Gibert, R Peck). Core and Workgroup
Chairs: B Agan, W Becker, C Brandt, J Edelman, N Gandhi, B
Gulanski, KMcGinnis, KA Oursler, L Park, C Rinaldo, K Sigel, J
Tate, E Wang, F P Wilson, J Womack.
UKRegister of HIV Seroconverters: Steering Committee: Andrew
Phillips (Chair), University College London (UCL), London;
Abdel Babiker, MRC CTU, London; Valerie Delpech, Public
Health England, London; Sarah Fidler, St Mary’s Hospital,
London; Martin Fisher, Brighton & Sussex University Hospitals
NHS Trust, Brighton; Julie Fox, Guys and St Thomas’ NHS
Trust/ Kings College, London; Richard Gilson, West London
Centre for Sexual Health, London; David Goldberg, Health
Protection Scotland, Glasgow; David Hawkins, Chelsea &
Westminster NHS Trust, London; Anne Johnson, UCL, London;
Margaret Johnson, UCL and Royal Free NHS Trust, London;
Ken McLean, West London Centre for Sexual Health, London;
Deenan Pillay, UCL, London; Frank Post, Kings College,
London. Collaborating clinical centres: N Kennedy, Monklands
Hospital, Airdrie; J Pritchard, Ashford Hospital, Ashford; U
Andrady, Ysbyty Gwynedd, Bangor; N Rajda, North Hampshire
Hospital, Basingstoke; C Donnelly, S McKernan, Royal Victoria
Hospital, Belfast; S Drake, G Gilleran, D White, Birmingham
Heartlands Hospital, Birmingham; J Ross, J Harding, R Faville,
Whittall Street Clinic, Birmingham; J Sweeney, P Flegg, S
Toomer, Blackpool Victoria Hospital, Blackpool; H Wilding, R
Woodward, Royal Bournemouth Hospital, Bournemouth; G
Dean, C Richardson, N Perry, Royal Sussex County Hospital,
Brighton; M Gompels, L Jennings, Southmead Hospital, Bristol;
D Bansaal, Queens Hospital, Burton-upon-Trent; M Browing, L
Connolly, Cardiff Royal Inﬁrmary, Cardiff; B Stanley, North
Cumbria Acute Hospitals NHS Trust, Carlisle; S Estreich, A
Magdy, St Helier Hospital, Carshalton; C O’Mahony, Countess
of Chester Hospital, Chester; P Fraser, Chesterﬁeld & North
Derbyshire Royal Hospital, Chesterﬁeld; SPR Jebakumar, Essex
County Hospital, Colchester; L David, Coventry & Warwick-
shire Hospital, Coventry; R Mette, Mayday University Hospital,
Croydon; H Summerﬁeld, Weymouth Community Hospital,
Dorset; M Evans, Ninewells Hospital, Dundee; C White,
University Hospital of North Durham, Durham; R Robertson,
Muirhouse Medical Group, Edinburgh; C Lean, S Morris,
Western General Hospital, Edinburgh; A Winter, Gartnavel
General Hospital & Glasgow Royal Inﬁrmary, Glasgow; S
Faulkner, Gloucestershire Royal Hospital, Gloucester; B Goor-
ney, Salford Hope Hospital, Greater Manchester; L Howard,
Farnham Road Hospital, Guildford; I Fairley, C Stemp,
Harrogate Hospital, Harrogate; L Short, Huddersﬁeld Royal
Inﬁrmary, Huddersﬁeld; M gomez, F young, St Mary’s Hospital
Isle of Wight; M Roberts, S Green, Kidderminster General
Hospital, Kidderminster; K Sivakumar, The Queen Elizabeth
Hospital, King’s Lynn; J Minton, A Siminoni, Leeds General
Inﬁrmary, Leeds; J Calderwood, D Greenhough, J Minton, St
James Hospital, Leeds; C DeSouza, LisaMuthern, COrkin, Barts
& The London NHS Trust, London; S Murphy, M Truvedi,
Central Middlesex Hospital, London; K McLean, Charing Cross
Hospital, London; D Hawkins, C Higgs, A Moyes, Chelsea &
Westminster Hospital, London; S Antonucci, S McCormack,
Dean Street Clinic, London; W Lynn, Ealing Hospital, London;
M Bevan, J Fox, A Teague, Guy’s & St Thomas NHS Trust,
London; J Anderson, S Mguni, Homerton Hospital, London; F
Post, L Campbell, E Wandolo King’s College Hospital, London;
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C Mazhude, H Russell, Lewisham University Hospital, London;
R Gilson, G Carrick, C Young Mortimer Market Centre,
London; J Ainsworth, A Waters, North Middlesex Hospital,
London; P Byrne, M Johnson, Royal Free Hospital, London;
London; S Fidler, K Kuldanek, S Mullaney, St Mary’s Hospital,
London; V Lawlor, RMelville, Whipps Cross Hospital, London;
A Sukthankar, S Thorpe, Manchester Royal Inﬁrmary, Man-
chester; C Murphy, E Wilkins, North Manchester General
Hospital, Manchester; S Ahmad, P Green, Withington Hospital,
Manchester; S Tayal, James Cook Hospital, Middlesbrough; E
Ong, Newcastle General Hospital, Newcastle; J Meaden,
Norfolk & Norwich University Hospital, Norwich; L Riddell,
City Hospital, Nottingham; D Loay, K Peacock, George Eliot
Hospital, Nunneaton; H Blackman, V Harindra, St Mary’s
Hospital, Portsmouth; AM Saeed, Royal Preston Hospital,
Preston; S Allen, U Natarajan, East Surrey Hospital, Redhill;
O Williams, Glan Clwyd District General, Rhyl; H Lacey, Baillie
Street Health Centre, Rochdale; C Care, C Bowman, S Herman,
Royal Hallamshire Hospital, Shefﬁeld; S V Devendra, J Wither,
Royal Shrewsbury Hospital, Shrewsbury; A Bridgwood, G Singh,
North Staffordshire Hospital, Stoke-on-Trent; S Bushby, Sunder-
land Royal Hospital, Sunderland; D Kellock, S Young, King’s
Mill Centre, Sutton-in-Ashﬁeld; G Rooney, B Snart, The Great
Western Hospital, Swindon; J Currie, M Fitzgerald, Taunton &
Somerset Hospital, Taunton; J Arumainayyagam, S Chandra-
mani, Manor Hospital, Walsall; S Rajamanoharan, T Robinson,
Watford General Hospital, Watford; M Roberts, Worcester
Royal Inﬁrmary, Worcester; O Williams, Maelor Hospital,
Wrexham; B Taylor, Wycombe General Hospital, Wycombe; C
Brewer, I Fairley, Monkgate Health Centre, York Hospital NHS
Trust, York.
PRIMO: JM Molina, B Loze (St Louis - Paris), P Morlat, M
Bonarek, F Bonnet, C Nouts, I Louis (St André - Bordeaux), F
Rafﬁ, V Reliquet, F Sauser, C Biron, O Mounoury, H Hue, D
Brosseau (Hotel Dieu - Nantes), JF Delfraissy, C Goujard, J
Ghosn, MT Rannou (Bicêtre – Le Kremlin Bicêtre), JF Bergmann,
E Badsi, A Rami, M Diemer, MParrinello (Lariboisière - Paris),
PM Girard, D Samanon-Bollens, P Campa, M Tourneur, N
Desplanques (St Antoine - Paris), JM Livrozet, F Jeanblanc, P
Chiarello, D Makhlouﬁ (E Herriot - Lyon), AP Blanc, T Allègre
(CHG - Aix en Provence), J Reynes, V Baillat, V Lemoing, C
Merle de Boever, C Tramoni (Gui de Chauliac - Montpellier), A
Cabié, G Sobesky, S Abel, V Beaujolais (CHU - Fort de France), G
Pialoux, L Slama, C Chakvetadze, V Berrebi (Tenon - Paris), P
Yeni, E Bouvet, I Fournier, J Gerbe (Bichat - Paris), C Trepo, K
Kofﬁ, C Augustin-Normand, P Miailhes, V Thoirain, C Brochier
(Hotel Dieu - Lyon), R Thomas, F Souala, M Ratajczak
(Pontchaillou - Rennes), J Beytoux, C Jacomet, F Gourdon (G
Montpied - Clermont-Ferrand), E Rouveix, S Morelon, C
Dupont, C Olivier (A Paré - Boulogne), O Lortholary, B Dupont,
JP Viard, A Maignan (Necker - Paris), JM Ragnaud, I Raymond
(Pellegrin - Bordeaux), C Leport, C Jadand, C Jestin, P Longuet, S
Boucherit (Bichat - Paris), D Sereni, C Lascoux, F Prevoteau (St
Louis - Paris), A Sobel, Y Levy, JD Lelièvre, AS Lascaux, S
Dominguez, C Dumont (H Mondor - Créteil), H Aumaître, B
Delmas, M Saada, MMedus (St Jean - Perpignan), L Guillevin, D
Salmon, T Tahi (Cochin - Paris), Y Yazdanpanah, S Pavel, MC
Marien (CH Dron - Tourcoing), B Drenou, G Beck-Wirth, C
Beck,M Benomar (EMuller -Mulhouse), C Katlama, R Tubiana,
H Ait Mohand, A Chermak, S Ben Abdallah (Pitié-Salpétrière -
Paris), M Bentata, F Touam, (Avicenne - Bobigny), B Hoen, C
Drobacheff, A Folzer (St Jacques - Besançon), P Massip, M
Obadia, L Prudhomme, E Bonnet, F Balzarin (Purpan -
Toulouse), E Pichard, JM Chennebault, P Fialaire, J Loison
(CHR - Angers), P Galanaud, F Boué, D Bornarel (Béclère -
Clamart), R Verdon, C Bazin, M Six, P Ferret (CHR Côte de
Nacre - Caen), L Weiss, D Batisse, G Gonzales-Canali, D Tisne-
Dessus (HEGP - Paris), A Devidas, P Chevojon, I Turpault
(Corbeil Essonnes), A Lafeuillade, A Cheret, G Philip (Chalucet -
Toulon), PMorel, J Timsit (St Louis - Paris), S Herson, N Amirat,
A Simon, C Brancion (Pitié-Salpétrière - Paris), J Cabane, O
Picard, J Tredup, N Desplanques (St Antoine - Paris), A Stein, I
Ravault (La Conception - Marseille), C Chavanet, M Buisson, S
Treuvetot (Bocage - Dijon), P Choutet, P Nau, F Bastides
(Bretonneau - Tours), T May, L Boyer, S Wassoumbou (CHU -
Nancy), E Oksenhendeler, L Gérard (St Louis - Paris), L Bernard,
P De Truchis, H Berthé (R Poincaré - Garches), Y Domart, D
Merrien (CH - Compiègne), A Greder Belan, (A Mignot - Le
Chesnay), M Gayraud, L Bodard, A Meudec (IMM Jourdan -
Paris), C Beuscart, C Daniel, E Pape (La Beauchée - St Brieuc), P
Vinceneux, AM Simonpoli, A Zeng (L Mourier - Colombes), L
Fournier (M Jacquet - Melun), JG Fuzibet, C Sohn, E Rosenthal,
M Quaranta (L’Archet - Nice), P Dellamonica, S Chaillou, M
Sabah (L’Archet - Nice), B Audhuy, A Schieber (L Pasteur -
Colmar), P Moreau, M Niault, O Vaillant (Bretagne Sud -
Lorient), G Huchon, A Compagnucci (Hotel-Dieu - Paris), I De
Lacroix Szmania, L Richier (Intercommunal - Créteil), I Lamaury
(Abymes - Pointe à Pitre), F Saint-Dizier, D Garipuy (Ducuing –
Toulouse), JA Gastaut, MPDrogoul, I PoizotMartin, G Fabre (St
Marguerite – Marseille), G Lambert de Cursay, B Abraham, C
Perino (CH - Brives), P Lagarde, F David (CH - Lagny), J Roche-
Sicot, JL Saraux, A Leprêtre (S Veil - Eaubonne), B Fampin, A
Uludag, ASMorin (Beaujon –Clichy), O Bletry, D Zucman (Foch
- Suresnes), A Regnier (CH - Vichy), JJ Girard (CH - Loches), DT
Quinsat, L Heripret (CH - Antibes), F Grihon (Haute Vallée de
l’Oise - Noyon), D Houlbert (CH - Alençon), M Ruel, K Chemlal
(CH - Nanterre), F Caron, Y Debab (C Nicolle - Rouen), F
Tremollieres, V Perronne (F Quesnay - Mantes La Jolie), G
Lepeu, B Slama (H Duffaut - Avignon), P Perré (Les Oudairies -
La Roche sur Yon), C Miodovski (Paris), G Guermonprez, A
Dulioust (CMC Bligny - Briis s/Forges), P Boudon, D Malbec (R
Ballanger - Aulnay s/bois), O Patey, C Semaille (CH - Villeneuve
St Georges), J Deville, G Remy, I Béguinot (CH - Reims).
SEROCO: Hopital Antoine Beclere, Clamart (P Galanaud, F
Boue, V Chambrin, C Pignon, GA Estocq, A Levy), Hopital de
Bicetre, Le Kremlin Bicetre (JF Delfraissy, C Goujard, M
Duracinsky, P Le Bras, MS Ngussan, D Peretti, N Medintzeff,
T Lambert, O Segeral, P Lezeau, Y Laurian), Hopital Europeen
Georges Pompidou, Paris (L Weiss, M Buisson, C Piketty, M
Karmochkine, D Batisse, M Eliaszewitch, D Jayle, D Tisne-
Dessus, M Kazatchkine), Hopital Bichat Claude Bernard, Paris
(C Leport, U Colasante, C Jadand, C Jestin, X Duval, W
Nouaouia, S Boucherit, JL Vilde), Hopital Saint Antoine, Paris
(PM Girard, D Bollens, D Binet, B Diallo, MC Meyohas, L
Fonquernie, JL Lagneau), Hopital Cochin, Paris (D Salmon,
LGuillevin, T Tahi, O Launay, MP Pietrie, D Sicard, N Stieltjes, J
Michot), Hopital Henri Mondor, Creteil (A Sobel, Y Levy, F
Bourdillon, AS Lascaux, JD Lelievre, C Dumont), Hopital
Necker, Paris (B Dupont, G Obenga, JP Viard, A Maignan),
Hopital Paul Brousse, Villjuif (D Vittecoq, L Escaut, C Bolliot),
Hopital Pitie Salpetriere, Paris (F Bricaire, C Katlama, L
Schneider, S Herson, A Simon, M Iguertsira), Hopital de la
Conception, Marseille (A Stein, C Tomei, I Ravaux, C Dhiver, H
Tissot Dupont, A Vallon, J Gallais, H Gallais), Hopital Sainte
Marguerite, Marseille (JA Gastaut, MP Drogoul, G Fabre),
Hopital de L’Archet, Nice (P Dellamonica, J Durant, VMondain,
I Perbost, JP Cassuto, JM Karsenti, H Venti, JG Fuzibet, E
Rosenthal, C Ceppi, M Quaranta), Hopital Avicenne, Bobigny
(JA Krivitsky, M Bentata, O Bouchaud, P Honore), Hopital Saint
Louis, Paris (D Sereni, C Lascoux, J Delgado), ACCTES / Hopital
Necker, Paris (C Rouzioux, M Burgard, L Boufassa), Hopital
Mignot, Le Chesnay (J Peynet).
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GEMES: Principal Investigator: R Muga/S Pérez-Hoyos. Data
analysis center: S Pérez-Hoyos, A Schiafﬁno Centro Nacional de
Epidemiología: J del Amo, D Alvarez, S Monge. Participating
centres: Cohorte del Hospital Germans Trias I Pujol, Badalona (R
Muga, A Sanvisens, B Clotet, J Tor, F Bolao, I Rivas, D Fuster),
Cohorte de Madrid-Sandoval (J del Romero, P Raposo, C
Rodríguez, M Vera), Cohorte de los CIPS de la Comunidad
Valenciana (I Hurtado, J Belda, E Fernandez, I Alastrue, C
Santos, T Tasa, A Juan, J Trullen), Cohortes de los CAS, de las
Prisiones de Cataluña y de hemofílicos del Hospital Vall
d’Hebron, Barcelona (P Garcia de Olalla, J Cayla, E Masdeu,
H Knobel, JM Mirò, MA Sambeat, R Guerrero, E Rivera),
Cohorte de hemofílicos del Hospital La Paz, Madrid (M
Quintana, C Gonzalez), Cohorte de Navarra (J Castilla, M
Guevara). Laboratory: C de Mendoza, N Zahonero, M Ortíz.
AMACS: Steering Committee: Antoniadou A, Chrysos G, Daikos
G, Gargalianos-Kakolyris P, Gogos HA, Katsarou O, Kordossis
T, LazanasM, Nikolaidis P, Panos G, Paparizos V, Paraskevis D,
Sambatakou H, Skoutelis A, Touloumi G (Chair). Coordinating
Center: Department of Hygiene, Epidemiology and Medical
Statistics, Athens University Medical School, Greece (Touloumi
G, Pantazis N, Vourli G, Gountas I, Gioukari V.)
Participating Centers: 4th Dept of Internal Medicine, Athens
Medical School, Attikon University Hospital (Antoniadou A,
Papadopoulos A, Petrikkos G); Infectious Disease Unit, “Tza-
neio” General Hospital of Pireaus (Chrysos G, Paraskeva D,
Hatziastros P); 1st Dept of Propedeutic Medicine, Athens
University, Medical School “Laikon” General Hopsital (Daikos
G, PsichogiouM); 1st Dept ofMedicine, Infectious Diseases Unit,
“G Gennimatas” Athens General Hospital (Gargalianos-Kako-
lyris P, Xylomenos G); 1st Dept of Internal Medicine, Infectious
Diseases Section, Patras University Hospital (Gogos HA,
Marangos MN, Panos G); Haemophilia Centre, 2nd Blood
Transfusion Centre, “Laikon” Athens General Hospital (Kat-
sarou O, Kouramba A, Ioannidou P); AIDS Unit, Dept of
Pathophysiology, “Laikon”Athens General Hospital and Athens
University, Medical School (Kordossis T, Kontos A); Infectious
Diseases Unit, Red Cross General Hospital of Athens (Lazanas
M, Chini M, Tsogas N); 1st Dept of Internal Medicine, Infectious
Diseases Devision, AHEPA University Hospital, Aristotle
University HIV Unit (Nikolaidis P, Kolaras P, Metallidis S);
2nd Internal Medicine Clinic, 1st IKA (Panos G, Haratsis G);
AIDS Unit, Clinic of Venereologic & Dermatologic Diseases,
Athens University, Medical School, Syngros Hospital (Paparizos
V, Leuow K, Kourkounti S); HIV Unit, 2nd Dpt of Internal
Medicine, Athens University, Medical School, Hippokration
General Hospital (Sambatakou H, Mariolis I); Infectious
Diseases & HIV Division, Dept of Internal Medicine, Evagge-
lismos Athens General Hospital (Skoutelis A, Papastamopoulos
V, Baraboutis I)
AQUITAINE: Principal investigator: Pr F Dabis. Scientiﬁc
committee: Prs F Bonnet, D Breilh, F Dabis, M Dupon, G
Chêne, H Fleury, D Malvy, P Mercié, I Pellegrin, P Morlat, D
Neau, JL Pellegrin, R Thiébaut; Drs S Bouchet, V Gaborieau, D
Lacoste, S Tchamgoué. Epidemiology and biostatistics: Prs G
Chêne, F Dabis, R Thiébaut, Drs M Bruyand, S Lawson-Ayayi, L
Wittkop. Clinical and biological hospital units: Bordeaux
University Hospital: Pr P Morlat (Pr F Bonnet, Drs N Bernard,
M Hessamfar, D Lacoste, MA Vandenhende); Pr M Dupon (Drs
FA Dauchy, H Dutronc), Pr M Longy-Boursier (Pr P Mercié, Drs
P Duffau, J Roger Schmeltz), Pr D Malvy (Drs T Pistone, MC
Receveur), Pr DNeau (Drs CCazanave, AOchoa,MOVareil), Pr
JL Pellegrin (Pr JF Viallard, Drs C Greib, E Lazaro); Pr H Fleury
(Pr ME Lafon, Drs S Reigadas, P Trimoulet); Pr D Breilh; Pr M
Molimard (Drs S Bouchet, K Titier); Pr JF Moreau (Dr I
Pellegrin); Drs F Haramburu, G Miremont-Salamé. Arcachon
Hospital: Dr A Dupont. Dax Hospital: Dr Y Gerard (Drs L
Caunègre, K André). Bayonne Hospital: Dr F Bonnal (Drs S
Farbos, MC Gemain). Libourne Hospital: Dr J Ceccaldi (Dr S
Tchamgoué). Mont-de-Marsan Hospital: Dr S De Witte (Dr C
Courtault). Pau Hospital: Drs E Monlun (Dr V Gaborieau).
PérigueuxHospital: Dr P Lataste (Dr JPMeraud). Villeneuve-sur-
Lot Hospital: Dr I Chossat. Permanent team: MJ Blaizeau, M
Bruyand, V Conte,MDecoin, J Delaune, S Delveaux, F Diarra, C
D’Ivernois, A Frosch, S Geffard, C Hannapier, S Lawson-Ayayi,
E Lenaud, O Leleux, F Le Marec, J Leray, I Louis, G Palmer, A
Pougetoux, X Sicard, D Touchard B Uwamaliya-Nziyumvira.
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